Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 357

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 357
---
, and medical professionals. These strategies include informative webinars, educational content and referrals, with the objective of generating awareness over the importance of clinical genetic tests for the health management of patients and their families. Mission and Strategy We aim to keep people healthy by revolutionizing personal health management, by delivering a comprehensive suite of services spanning prevention, diagnosis and prognosis, integrating a wide range of clinical, biological, and lifestyle data with advanced artificial intelligence, empowering people to make informed health choices and live healthier lives. Our strategy for long -termsustainable expansion is grounded in fundamental drivers that form the core of our business operations. It is our belief that these drivers function collaboratively to reinforce and broad our role in the emerging markets we are developing, which include the following: • Data -driven approach for health management: we are committed to providing preventative health solutions and precise clinical genetic services through our operating segments, Rewell and Heritas Diagnostics. By leveraging technology and data acquisition methods, we are able to train machine learning models that integrate our genetic, microbiome, lifestyle and/or clinical data to deliver more accurate results and foster scientific development. We perform clinical studies under stringent GCP standards to maximize the good quality of our results and comply with the regulatory agencies. We continuously collect diverse omni -modaldata across our product offerings to build robust Latin American genomic data bases. This localized approach addresses the challenges faced other players in the region who rely on foreign markets for sample processing, often resulting in inaccurate outcomes due to the absence of region -specificdata. • Artificial intelligence: from the foundation AI models in genomics to the development of clinically oriented LLMs, we apply algorithms to improve the quality of our results. Through our product offering we plan on providing genomic sequencing, proprietary data processing, and comprehensive artificial intelligence analysis to further develop our current and future products. Additionally, we value the use of technology breakthroughs and advancements in self and remote testing, as we plan on collecting complete omni -modaldata to accelerate our innovations, improve localized results and develop future products. • Customer experience: we view customer experience for patients, physicians, healthcare providers, and partners as a fundamental element of our long -termgrowth strategy and a powerful tool to facilitate the integration of genetics into mainstream medicine. We believe that providing excellent products and ensuring 184 “ease -of -use,” such as onboarding, streamlined ordering, results interpretation and fast turnaround times, are key for all our customers. As such, our products and services are developed based on user insights, local languages and cultures,